Table 2. Variables collected for the 8^th edition and for the 9^th edition.

Variables		Variables database 8th edition	News 9th edition
General features		Age, race, sex, smoking, weight loss in the previous 6 months, performance status, specific weight, height, and comorbidities (Colinet score: Smoking, kidney failure, cardiovascular, respiratory, neoplastic comorbidities, alcoholism).
Diagnostic descriptors		Inclusion date, detection method, diagnostic confirmation (histological or cytological), location of the primary tumor, degree of tumor differentiation, histological type.
		Small cell tumors: Paraneoplastic syndromes and type.
Laboratory variables		LDH, Hb, Ca, Na, ALP, ALB, white blood cell, neutrophils, and platelets count
Lung function		FVC; FEV1
PET		SUV values: Primary tumor and for lymph nodes.
TNM pre-treatment descriptors.		Clinical characteristics of the tumor, size, and extension.
		Carcinomatosis lymphangitis.
		Nodal involvement evaluation confirmed by biopsy or cytology
Treatment	Nonsurgical treatment	Clinical TNM.	Immunotherapy
		Chemotherapy, radiotherapy and radiation area.
	Surgical treatment	Type, extent, and degree of resection (complete, incomplete, or uncertain).	STAS
		Adjuvant treatment with chemotherapy and/or radiotherapy. Clinical and pathologic TNM.
		• T-component: Pleural extension, vascular invasion, fissure situation, lymphatic and perineural invasion, and cytology of pleural lavage.
		• N-component: Number of nodes explored, number of positive nodes, extracapsular involvement. All by regions N3, N2, and N1.
		• M-component: Findings that imply changes in the indication of radical surgical treatment.
Multiple nodes secondary to primary tumor		Size, histology, and distance of the nodules in relation to the primary tumor.
Synchronous multiple tumors		Staging data for each lesion will be collected separately and independently for each lesion.
Follow-up Molecular parameters		Follow-up date, situation in relation to the tumor, relapse and date, date of exitus.
			Genetic biomarkers, type of mutation, and detection technique. Type of sample. Protein alterations: Type, detection technique, sample type, antibody used.

*Clinical history and examinations – radiology, PET, bronchoscopy, necessary invasive, or surgical examinations that do not include therapeutic resection of the tumor. **The lymph node evaluation will be carried out following the node map published by the IASLC in 2009. PET: Positron emission tomography; LDH: Lactate dehydrogenase; Hb Hemoglobin; Ca: Calcium; NA: Sodium; ALP: Alkaline phosphatase; FVC: Forced vital capacity; FEV1: Forced expiratory volume in the 1^st second; SUV: Standardized uptake value; STAS: Presence of free cells in the alveolar space